56166
document
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease . OBJECTIVE To assess the mechanism of long-term LDL-C-lowering effect of ezetimibe-plus-statin . METHODS Coronary artery disease patients whose LDL-C ≥ 70 mg/dL after treatment with atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day were randomly assigned to receive ezetimibe 10 mg/day + statin ( n = 78 ) or double-dose statin ( n = 72 ) for 52 weeks . RESULTS Greater LDL-C reduction was observed and maintained until 52 weeks in ezetimibe-plus-statin , while LDL-C levels re-increased after 12 weeks in double-dose statin . Although lathosterol/TC increased , campesterol/TC decreased more in ezetimibe-plus-statin . In contrast , lathosterol/TC unchanged and campesterol/TC increased , increasing campesterol/lathosterol ratio for 52 weeks in double-dose statin . Plasma PCSK9 levels were higher in double-dose statin than in ezetimibe-plus-statin at 12 weeks , but similar at 52 weeks . CONCLUSION Although the difference in PCSK9 between 2 groups was transient , that in both campesterol and lathosterol persisted until 52 weeks . These results demonstrated simultaneous inhibition of cholesterol absorption and synthesis provides stable and greater decrease in LDL-C levels .
56167
Intervention_Pharmacological
ezetimibe-plus-statin
56168
Intervention_Control
double-dose statin therapy
56169
Intervention_Pharmacological
ezetimibe-plus-statin
56170
Outcome_Physical
low-density lipoprotein cholesterol levels
56171
Participant_Condition
patients with coronary artery disease .
56172
Participant_Condition
Coronary artery disease patients whose LDL-C ≥ 70 mg/dL after treatment with atorvastatin 10 mg/day or rosuvastatin 2.5 mg/day